Editorial overview: Preface to ‘a tribute to professor Norman Bowery’
Section snippets
Thomas P Blackburn is an internationally recognized neuroscientist whose industry experience embraces both major pharmaceutical, biotech and virtual drug development companies. His expertise in neuropharmacology and clinical drug development led to several drugs that entered clinical development including the antidepressant Seroxat®/Paxil®. He is President Emeritus of the British Pharmacological Society and a director of biotech start-ups. Tom worked with his friend and colleague Norman Bowery
References (4)
- et al.
Light microscopic autoradiography localisation of [3H]glycine and [3H]strychnine binding sites in rat brain
Eur J Pharmacol
(1986) - et al.
Pharmacology of absence epilepsy
TiPS
(2003)
Cited by (0)
Thomas P Blackburn is an internationally recognized neuroscientist whose industry experience embraces both major pharmaceutical, biotech and virtual drug development companies. His expertise in neuropharmacology and clinical drug development led to several drugs that entered clinical development including the antidepressant Seroxat®/Paxil®. He is President Emeritus of the British Pharmacological Society and a director of biotech start-ups. Tom worked with his friend and colleague Norman Bowery on several of neuroscience projects over 35 years.
David G Trist has spent all of his working life within the pharmaceutical industry mainly in the fields of the Central Nervous System (CNS) and Cardiovascular. He has published mostly on calcium antagonists, excitatory amino acids and neuropeptides with particular interest in drug-receptor interactions. He is presently Co-Editor in Chief of COPHAR. David knew Norman Bowery since 1987, as a friend, collaborator and colleague.